TxCell - Tr1 pathway to cure immune diseases - Clinical Trial PI/IIa Project

June, 2010: TxCell announces the successfull completion of the Preclinical Development of TX-RAD in Inflammatory Arthritis

April, 2010: TxCell announces Positive Preliminary Results from the Phase I/IIa clinical trial of OvaSave in Crohn's Disease

January, 2010: TxCell appoints Miguel Forte Chief Medical Officer

July, 2009: The collaboration project with TxCell, TcLand, INSERM U844/CHRU Montpellier, has been approuved by the French Public Institutions for the development of Tr1 cell-based technology in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis.

Clinical Trial PI/IIa Project

RATS: Rheumatoid Arthritis and Tr1 cells Study

RATS is a phase I/IIa clinical trial project to evaluate the safety and efficacy of TxCell's Tr1 cell technology in patients with Rheumatoid Arthritis (TX-RAD).
This study will be initiated after completion of all preclinical studies and will be submitted to the Health Authorities end 2010.

[ Retour ]

Products